Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Alector, Inc. (ALEC) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
10/10/2023 SC 13G/A FIL Ltd reports a 14.5% stake in ALECTOR INC
08/03/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 8-K Quarterly results
Docs: "Alector Reports Second Quarter 2023 Financial Results and Provides Business Update Closed screening in the INVOKE-2 Phase 2 trial of AL002 in participants with early Alzheimer’s disease; completing enrollment in Q3 2023, with data readout expected in Q4 2024 Presented update on INVOKE-2 at the Alzheimer’s Association International Conference Anticipate completing enrollment in pivotal INFRONT-3 trial of latozinemab with symptomatic FTD-GRN participants in Q4 2023 based on recent interactions with the FDA and EMA $630.0 million in cash, cash equivalents and investments provide runway through 2025; revenue and expense guidance updated for 2023 Management to host conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT South San Francisco, Calif.,"
06/01/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/08/2023 EFFECT Form EFFECT - Notice of Effectiveness:
05/04/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/04/2023 8-K Quarterly results
05/02/2023 POS AM Form POS AM - Post-Effective amendments for registration statement:
05/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
04/27/2023 8-K Quarterly results
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/29/2023 8-K Quarterly results
03/13/2023 8-K Regulation FD Disclosure  Interactive Data
02/28/2023 S-3 Form S-3 - Registration statement under Securities Act of 1933:
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
Docs: "Alector Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update On track to complete enrollment in the INVOKE-2 Phase 2 clinical trial of AL002 in patients with early Alzheimer’s disease in Q3 2023, with data readout expected by Q4 2024 Preparing to engage with regulatory authorities in mid-2023 and targeting data readout from the pivotal INFRONT-3 clinical trial for latozinemab in early 2025 pending regulatory feedback Additional data from the INFRONT-2 Phase 2 clinical trial of latozinemab in FTD-C9orf72 expected during the second half of 2023 Company and GSK plan to advance AL101 program in 2023, with the initiation of a PK bridging study to be followed by a global Phase 2 clinical trial in early Alzheimer’s disease $712.9 million in cash, cash equivale..."
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A EcoR1 Capital, LLC reports a 4.9% stake in Alector, Inc.
02/09/2023 SC 13G/A VANGUARD GROUP INC reports a 7.7% stake in Alector Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A FMR LLC reports a 5.7% stake in ALECTOR INC
02/07/2023 SC 13G/A Polaris Venture Partners VI, L.P. reports a 14.4% stake in Alector, Inc.
02/01/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
11/08/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/08/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
08/04/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/04/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy